Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Nov 2, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K

Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery.

Yiping Chen1, Dongyu Sun1, Ruojing Yang1

  • 1Department of Quantitative Bioscience, Merck & Co., Inc., Boston, MA, USA.

SLAS Discovery : Advancing Life Sciences R & D
|June 16, 2021
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of MK-2118, a Small-Molecule Agonist of STING.

ACS medicinal chemistry letters·2026
Same author

Contrast-enhanced MRI improves the diagnostic performance for vaginal fornix invasion in cervical carcinoma.

Insights into imaging·2026
Same author

Amplification-free dual-blocking autocatalytic CRISPR-Cascade for attomolar DNA detection with low nonspecific signal.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Discovery of Potent 1,3-Cyclobutane-Containing Dual A<sub>2A</sub>/A<sub>2B</sub> Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer.

ACS medicinal chemistry letters·2026
Same author

Discovery of MK-1088 as a Potent A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy.

Journal of medicinal chemistry·2026
Same author

Stimuli-responsive copper-iodide nanoparticles for low-dose X-ray-induced photodynamic therapy and enhanced cuproptosis.

Acta biomaterialia·2026

Developing a novel assay for Interleukin-1 receptor-associated kinase 4 (IRAK4) engagement improves preclinical drug discovery. This proximal cellular assay aids in identifying selective IRAK4 inhibitors for inflammatory diseases, enhancing therapeutic success rates.

Area of Science:

  • Pharmacology and Drug Discovery
  • Immunology and Inflammation

Background:

  • Lack of specific target engagement is a major cause of drug failure in late-stage clinical trials.
  • Early preclinical assessment of proximal target engagement can increase the success rate of new therapeutics.
  • Interleukin-1 receptor-associated kinase 4 (IRAK4) is a kinase implicated in inflammatory and autoimmune diseases.

Purpose of the Study:

  • To establish a proximal, functional assay for evaluating IRAK4 target engagement in a cellular context.
  • To support structure-activity relationship (SAR) studies for the identification and optimization of selective IRAK4 inhibitors.
  • To validate the biological relevance of IRAK1 activation as a biomarker for IRAK4 activity.

Main Methods:

  • Development of an electrochemiluminescence (ECL)-based cellular assay measuring endogenous IRAK1 activation.
Keywords:
IRAK1IRAK4assay agreementhigh throughputtarget engagement

More Related Videos

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.2K
Using High Content Imaging to Quantify Target Engagement in Adherent Cells
07:23

Using High Content Imaging to Quantify Target Engagement in Adherent Cells

Published on: November 29, 2018

8.8K

Related Experiment Videos

Last Updated: Nov 2, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.2K
Using High Content Imaging to Quantify Target Engagement in Adherent Cells
07:23

Using High Content Imaging to Quantify Target Engagement in Adherent Cells

Published on: November 29, 2018

8.8K
  • Utilized IRAK1 activation assay to assess IRAK4 engagement across different compound classes.
  • Correlated assay data with IRAK4 biochemical kinase activity and TNFα secretion assays from peripheral blood mononuclear cells (PBMCs).

    • Main Results:

    • The developed IRAK1 activation assay demonstrated statistically significant correlations with IRAK4 kinase activity and functional PBMC assays.
    • Assay validation confirmed IRAK1 engagement as a relevant biomarker for IRAK4 activity.
    • The assay exhibited plate uniformity and potency reproducibility, indicating suitability for high-throughput screening.

    Conclusions:

    • The proximal cellular IRAK1 activation assay is a valuable tool for early preclinical assessment of IRAK4 inhibitors.
    • Incorporating this assay into in vitro screening can prevent optimization towards off-target activities.
    • This approach enhances the likelihood of developing successful therapeutics for inflammatory and autoimmune diseases.